



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

| |
|----------------------------|
| To NZX Limited; and |
| Name of listed issuer: |
| Date this disclosure made: |
| Date of last disclosure: |

| |
|--|
| Fisher & Paykel Healthcare Corporation Limited |
| 7 April 2025 |
| 11 March 2025 |

Director or senior manager giving disclosure

| |
|---|
| Full name(s): |
| Name of listed issuer: |
| Name of related body corporate (if applicable): |
| Position held in listed issuer: |

| |
|--|
| Andrew Robert Donald Somervell |
| Fisher & Paykel Healthcare Corporation Limited |
| |
| Vice President - Products & Technology |

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

| |
|--|
| Class of affected quoted financial products: |
| Nature of the affected relevant interest(s): |

| |
|---|
| Ordinary Shares |
| Beneficial interest in shares issued to trustees under an Employee Share Scheme |

For that relevant interest-

| |
|--|
| Number held in class before acquisition or disposal: |
| Number held in class after acquisition or disposal: |
| Current registered holder(s): |
| Registered holder(s) once transfers are registered: |

| |
|--------------------------------|
| 110,322 Ordinary Shares |
| 110,351 Ordinary Shares |
| Andrew Robert Donald Somervell |
| Andrew Robert Donald Somervell |

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

| |
|---|
| Type of affected derivative: |
| Class of underlying financial products: |

| |
|--|
| |
| |

Details of affected derivative-

| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative(if any): |
| The price specified in the terms of the derivative (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

| |
|--|
| |
| |
| |
| |
| |
| |

For that derivative,-

| |
|--|
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |

Details of transactions giving rise to acquisition or disposal

| |
|---|
| Total number of transactions to which notice relates: |
|---|

| |
|-----|
| One |
|-----|

Details of transactions requiring disclosure-

| |
|---|
| Date of transaction: |
| Nature of transaction: |
| Name of any other party or parties to the transaction (if known): |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: |
| Number of financial products to which the transaction related: |

| |
|--|
| 4 April 2025 |
| Participation in Employee Share Purchase Scheme |
| Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited |
| \$978.00 |
| 29 Ordinary Shares |

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

| |
|--|
| Whether relevant interests were acquired or disposed of during a closed period: |
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: |
| Date of the prior written clearance (if any): |

| |
|--|
| |
| |
| |

Summary of other relevant interests after acquisition or disposal:

| |
|---|
| Class of quoted financial products: |
| Nature of relevant interest: |
| <i>For that relevant interest,-</i> |
| Number held in class: |
| Current registered holder(s): |
| <i>For a derivative relevant interest,-</i> |
| Type of derivative: |

| |
|---------------------------------------|
| a) Options to acquire Ordinary Shares |
| b) Performance Share Rights |
| Beneficial Interest |

| |
|------------------------------------|
| a) 144,531 Options |
| b) 49,717 Performance Share Rights |
| Andrew Robert Donald Somervell |

| |
|--|
| |
|--|

Details of derivative,-


| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative (if any): |
| The price's specified terms (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |
| <i>For that derivative relevant interest,-</i> |
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |
| |
| |
| |
| |
| |
| |
| |

Certification

| |
|--|
| I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. |
| Signature of director or officer: |
| Date of signature: |
| or |
| Signature of person authorised to sign on behalf of director or officer: |
| Date of signature: |
| Name and title of authorised person: |

| |
|--|
| |
| |

| |
|--|
|  |
| 7 April 2025 |
| Raelene Leonard, General Counsel & Company Secretary |



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

| |
|----------------------------|
| To NZX Limited; and |
| Name of listed issuer: |
| Date this disclosure made: |
| Date of last disclosure: |

| |
|--|
| Fisher & Paykel Healthcare Corporation Limited |
| 7 April 2025 |
| 11 March 2025 |

Director or senior manager giving disclosure

| |
|---|
| Full name(s): |
| Name of listed issuer: |
| Name of related body corporate (if applicable): |
| Position held in listed issuer: |

| |
|--|
| Andrew Grant Niccol |
| Fisher & Paykel Healthcare Corporation Limited |
| |
| Chief Operating Officer |

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

| |
|--|
| Class of affected quoted financial products: |
| Nature of the affected relevant interest(s): |

| |
|---|
| Ordinary Shares |
| Beneficial interest in shares issued to trustees under an Employee Share Scheme |

For that relevant interest-

| |
|--|
| Number held in class before acquisition or disposal: |
| Number held in class after acquisition or disposal: |
| Current registered holder(s): |
| Registered holder(s) once transfers are registered: |

| |
|-----------------------|
| 3,500 Ordinary Shares |
| 3,559 Ordinary Shares |
| Andrew Grant Niccol |
| Andrew Grant Niccol |

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

| |
|---|
| Type of affected derivative: |
| Class of underlying financial products: |

| |
|--|
| |
| |

Details of affected derivative-

| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative(if any): |
| The price specified in the terms of the derivative (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

| |
|--|
| |
| |
| |
| |
| |
| |

For that derivative,-

| |
|--|
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |

Details of transactions giving rise to acquisition or disposal

| |
|---|
| Total number of transactions to which notice relates: |
|---|

| |
|-----|
| One |
|-----|

Details of transactions requiring disclosure-

| |
|---|
| Date of transaction: |
| Nature of transaction: |
| Name of any other party or parties to the transaction (if known): |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: |
| Number of financial products to which the transaction related: |

| |
|--|
| 4 April 2025 |
| Participation in Employee Share Purchase Scheme |
| Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited |
| \$1,989.72 |
| 59 Ordinary Shares |

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

| |
|--|
| Whether relevant interests were acquired or disposed of during a closed period: |
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: |
| Date of the prior written clearance (if any): |

| |
|--|
| |
| |
| |

Summary of other relevant interests after acquisition or disposal:

| |
|---|
| Class of quoted financial products: |
| Nature of relevant interest: |
| <i>For that relevant interest,-</i> |
| Number held in class: |
| Current registered holder(s): |
| <i>For a derivative relevant interest,-</i> |
| Type of derivative: |

| |
|---------------------------------------|
| a) Options to acquire Ordinary Shares |
| b) Performance Share Rights |
| Beneficial Interest |

| |
|------------------------------------|
| a) 34,587 Options |
| b) 12,011 Performance Share Rights |
| Andrew Grant Niccol |

| |
|--|
| |
|--|

Details of derivative,-


| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative (if any): |
| The price's specified terms (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |
| <i>For that derivative relevant interest,-</i> |
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |
| |
| |
| |
| |
| |
| |
| |

Certification

| |
|--|
| I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. |
| Signature of director or officer: |
| Date of signature: |
| or |
| Signature of person authorised to sign on behalf of director or officer: |
| Date of signature: |
| Name and title of authorised person: |

| |
|--|
| |
| |

| |
|--|
|  |
| 7 April 2025 |
| Raelene Leonard, General Counsel & Company Secretary |



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

| |
|----------------------------|
| To NZX Limited; and |
| Name of listed issuer: |
| Date this disclosure made: |
| Date of last disclosure: |

| |
|--|
| Fisher & Paykel Healthcare Corporation Limited |
| 7 April 2025 |
| 11 March 2025 |

Director or senior manager giving disclosure

| |
|---|
| Full name(s): |
| Name of listed issuer: |
| Name of related body corporate (if applicable): |
| Position held in listed issuer: |

| |
|--|
| Lewis George Gradon |
| Fisher & Paykel Healthcare Corporation Limited |
| |
| Chief Executive Officer |

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

| |
|--|
| Class of affected quoted financial products: |
| Nature of the affected relevant interest(s): |

| |
|---|
| Ordinary Shares |
| Beneficial interest in shares issued to trustees under an Employee Share Scheme |

For that relevant interest-

| |
|--|
| Number held in class before acquisition or disposal: |
| Number held in class after acquisition or disposal: |
| Current registered holder(s): |
| Registered holder(s) once transfers are registered: |

| |
|--|
| 574,165 Ordinary Shares |
| 574,224 Ordinary Shares |
| Lewis George Gradon; Gradon Family Trust |
| Lewis George Gradon; Gradon Family Trust |

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

| |
|---|
| Type of affected derivative: |
| Class of underlying financial products: |

| |
|--|
| |
| |

Details of affected derivative-

| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative (if any): |
| The price specified in the terms of the derivative (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

| |
|--|
| |
| |
| |
| |
| |
| |

For that derivative,-

| |
|--|
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |

Details of transactions giving rise to acquisition or disposal

| |
|---|
| Total number of transactions to which notice relates: |
|---|

| |
|-----|
| One |
|-----|

Details of transactions requiring disclosure-

| |
|---|
| Date of transaction: |
| Nature of transaction: |
| Name of any other party or parties to the transaction (if known): |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: |
| Number of financial products to which the transaction related: |
| <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i> |
| Whether relevant interests were acquired or disposed of during a closed period: |
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: |
| Date of the prior written clearance (if any): |

| |
|--|
| 4 April 2025 |
| Participation in Employee Share Purchase Scheme |
| Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited |
| \$1,989.72 |
| 59 Ordinary Shares |

Summary of other relevant interests after acquisition or disposal:

| |
|---|
| Class of quoted financial products: |
| Nature of relevant interest: |
| <i>For that relevant interest,-</i> |
| Number held in class: |
| Current registered holder(s): |
| <i>For a derivative relevant interest,-</i> |
| Type of derivative: |

| |
|---------------------------------------|
| a) Options to acquire Ordinary Shares |
| b) Performance Share Rights |
| a) Beneficial Interest |
| b) Beneficial Interest |
| a) 470,992 Options |
| b) 159,726 Performance Share Rights |
| a) Lewis George Gradon |
| b) Lewis George Gradon |

Details of derivative,-

| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative (if any): |
| The price's specified terms (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |
| <i>For that derivative relevant interest,-</i> |
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |
| |
| |
| |
| |
| |
| |
| |

Certification

| |
|--|
| I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. |
| Signature of director or officer: |
| Date of signature: |
| or |
| Signature of person authorised to sign on behalf of director or officer: |
| Date of signature: |
| Name and title of authorised person: |

| |
|---|
| |
| |
| |
| <i>Raelene Leonard</i> |
| 7 April 2025 |
| Raelene Leonard, General Counsel & Company Secretary |



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

| | |
|----------------------------|--|
| To NZX Limited; and | |
| Name of listed issuer: | Fisher & Paykel Healthcare Corporation Limited |
| Date this disclosure made: | 7 April 2025 |
| Date of last disclosure: | 11 March 2025 |

Director or senior manager giving disclosure

| | |
|---|--|
| Full name(s): | Lyndal Jane York |
| Name of listed issuer: | Fisher & Paykel Healthcare Corporation Limited |
| Name of related body corporate (if applicable): | |
| Position held in listed issuer: | Chief Financial Officer |

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

| | |
|--|---|
| Class of affected quoted financial products: | Ordinary Shares |
| Nature of the affected relevant interest(s): | Beneficial interest in shares issued to trustees under an Employee Share Scheme |

For that relevant interest-

| | |
|--|--|
| Number held in class before acquisition or disposal: | 26,525 Ordinary Shares |
| Number held in class after acquisition or disposal: | 26,557 Ordinary Shares |
| Current registered holder(s): | Lyndal Jane York and Alexander Eric York |
| Registered holder(s) once transfers are registered: | Lyndal Jane York and Alexander Eric York |

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

| | |
|---|--|
| Type of affected derivative: | |
| Class of underlying financial products: | |

Details of affected derivative-

| | |
|---|--|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): | |
| A statement as to whether the derivative is cash settled or physically settled: | |
| Maturity date of the derivative (if any): | |
| Expiry date of the derivative(if any): | |
| The price specified in the terms of the derivative (if any): | |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: | |

For that derivative,-

| | |
|--|--|
| Parties to the derivative: | |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: | |

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

One

Details of transactions requiring disclosure-

Date of transaction:

4 April 2025

Nature of transaction:

Participation in Employee Share Purchase Scheme

Name of any other party or parties to the transaction (if known):

Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$896.99

Number of financial products to which the transaction related:

32 Ordinary Shares

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

a) Options to acquire Ordinary Shares
b) Performance Share Rights

Nature of relevant interest:

a) Beneficial Interest
b) Beneficial Interest*For that relevant interest,-*

Number held in class:

a) 203,534 Options
b) 74,560 Performance Share Rights

Current registered holder(s):

a) Lyndal Jane York
b) Lyndal Jane York*For a derivative relevant interest,-*

Type of derivative:

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:


Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:



7 April 2025

Raelene Leonard,
General Counsel & Company Secretary